BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-96. [PMID: 19412008 DOI: 10.1097/MPG.0b013e31818e04d1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: Preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009; 15(48): 6017-6022 [PMID: 20027672 DOI: 10.3748/wjg.15.6017] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
2 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
3 Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, Dong XC, Yin XM. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol. 2013;58:993-999. [PMID: 23339953 DOI: 10.1124/10.1016/j.jhep.2013.01.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
5 Moura LP, Figueredo GA, Bertolini NO, Ceccato M, Pereira JR, Sponton AC, de Mello MA. Dietary restriction, caloric value and the accumulation of hepatic fat. Lipids Health Dis 2012;11:2. [PMID: 22221448 DOI: 10.1186/1476-511X-11-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
6 Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol. 2014;20:143-153. [PMID: 24976277 DOI: 10.4103/1319-3767.132983] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
7 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(42): 15518-15531 [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
8 S Lavekar A, V Raje D, Manohar T, A Lavekar A. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian J Hepatogastroenterol 2017;7:130-7. [PMID: 29201794 DOI: 10.5005/jp-journals-10018-1233] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
9 Koot BG, van der Baan-Slootweg OH, Vinke S, Bohte AE, Tamminga-Smeulders CL, Jansen PL, Stoker J, Benninga MA. Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int J Obes (Lond) 2016;40:51-7. [PMID: 26315844 DOI: 10.1038/ijo.2015.175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
10 Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2014; 20(2): 569-577 [PMID: 24574727 DOI: 10.3748/wjg.v20.i2.569] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
11 Yanovski JA. Pediatric obesity. An introduction. Appetite 2015;93:3-12. [PMID: 25836737 DOI: 10.1016/j.appet.2015.03.028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
12 Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J, Sanhueza E, Contreras J, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol 2014; 20(34): 12182-12201 [PMID: 25232252 DOI: 10.3748/wjg.v20.i34.12182] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
13 Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol 2015; 21(6): 1691-1702 [PMID: 25684933 DOI: 10.3748/wjg.v21.i6.1691] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 71] [Article Influence: 12.0] [Reference Citation Analysis]
14 Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, De Micco I, Paolella G, Parenti G. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr. 2012;38:55. [PMID: 23075296 DOI: 10.1186/1824-7288-38-55] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
15 Bouglé D, Zunquin G, Sesbouë B, Sabatier JP. Relationships of cardiorespiratory fitness with metabolic risk factors, inflammation, and liver transaminases in overweight youths. Int J Pediatr 2010;2010:580897. [PMID: 20652084 DOI: 10.1155/2010/580897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
16 Di Sessa A, Cirillo G, Guarino S, Marzuillo P, Miraglia Del Giudice E. Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management. Pediatric Health Med Ther 2019;10:89-97. [PMID: 31692530 DOI: 10.2147/PHMT.S188989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
17 Abdel-Maboud M, Menshawy A, Menshawy E, Emara A, Alshandidy M, Eid M. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol 2020;13:1756284820974917. [PMID: 33335561 DOI: 10.1177/1756284820974917] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne) 2021;8:595371. [PMID: 33718398 DOI: 10.3389/fmed.2021.595371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
19 Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2013; 19(40): 6911-6918 [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911] [Cited by in CrossRef: 195] [Cited by in F6Publishing: 174] [Article Influence: 21.7] [Reference Citation Analysis]
20 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56:461-468. [PMID: 23287807 DOI: 10.1016/j.numecd.2012.02.007] [Cited by in Crossref: 229] [Cited by in F6Publishing: 235] [Article Influence: 25.4] [Reference Citation Analysis]
21 Paolella G, Pisano P, Albano R, Cannaviello L, Mauro C, Esposito G, Vajro P. Fatty liver disease and hypertransaminasemia hiding the association of clinically silent Duchenne muscular dystrophy and hereditary fructose intolerance. Ital J Pediatr. 2012;38:64. [PMID: 23114028 DOI: 10.1186/1824-7288-38-64] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
22 Corte CD, Ferrari F, Villani A, Nobili V. Epidemiology and Natural History of NAFLD. J Med Biochem 2015;34:13-7. [PMID: 28356818 DOI: 10.2478/jomb-2014-0049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
23 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
24 El-Shabrawi MH, Kamal NM. Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases. Paediatr Drugs 2011;13:357-70. [PMID: 21999649 DOI: 10.2165/11591610-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
25 Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20:395. [PMID: 30658519 DOI: 10.3390/ijms20020395] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 27.3] [Reference Citation Analysis]
26 Hattar LN, Wilson TA, Tabotabo LA, Smith EO, Abrams SH. Physical activity and nutrition attitudes in obese Hispanic children with non-alcoholic steatohepatitis. World J Gastroenterol 2011; 17(39): 4396-4403 [PMID: 22110265 DOI: 10.3748/wjg.v17.i39.4396] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
27 Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404. [PMID: 22194737 DOI: 10.1155/2012/716404] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 8.9] [Reference Citation Analysis]
28 Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH. THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta Endocrinol (Buchar) 2020;16:223-31. [PMID: 33029240 DOI: 10.4183/aeb.2020.223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci 2020;21:E1907. [PMID: 32168769 DOI: 10.3390/ijms21061907] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
30 de Moura LP, Sponton AC, de Araújo MB, Dalia RA, Pauli JR, Rostom de Mello MA. Moderate physical activity from childhood contributes to metabolic health and reduces hepatic fat accumulation in adult rats. Lipids Health Dis 2013;12:29. [PMID: 23496920 DOI: 10.1186/1476-511X-12-29] [Cited by in Crossref: 7] [Article Influence: 0.8] [Reference Citation Analysis]
31 Janczyk W, Socha P, Lebensztejn D, Wierzbicka A, Mazur A, Neuhoff-Murawska J, Matusik P. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr. 2013;13:85. [PMID: 23702094 DOI: 10.1186/1471-2431-13-85] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
32 Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, Dong XC, Yin XM. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol. 2013;58:993-999. [PMID: 23339953 DOI: 10.1016/j.jhep.2013.01.011] [Cited by in Crossref: 233] [Cited by in F6Publishing: 237] [Article Influence: 25.9] [Reference Citation Analysis]
33 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013;56:461-8. [PMID: 23287807 DOI: 10.1097/MPG.0b013e318284abb5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 59] [Article Influence: 13.0] [Reference Citation Analysis]